JERSEY CITY, N.J., April 15, 2025--(BUSINESS WIRE)--Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira ...

Organon (OGN) closed at $11.30 in the latest trading session, marking a +1.07% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.79% for the day. Elsewhere, the ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of ...

Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global ...

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Organon & Co (Symbol: OGN) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

In the latest market close, Organon (OGN) reached $14.56, with a -1.02% movement compared to the previous day. The stock fell short of the S&P 500, which registered a loss of 0.33% for the day. On the ...